首页 | 本学科首页   官方微博 | 高级检索  
检索        

康莱特注射液联合化疗治疗非小细胞肺癌临床观察
引用本文:侯恩存.康莱特注射液联合化疗治疗非小细胞肺癌临床观察[J].中药新药与临床药理,2008,19(6).
作者姓名:侯恩存
作者单位:广西中医学院附属瑞康医院肿瘤科,南宁,530011
摘    要:目的观察康莱特注射液联合长春瑞滨 顺铂(NP)治疗晚期非小细胞肺癌的疗效及不良反应。方法将经病理确诊的晚期非小细胞肺癌患者随机分为两组,对照组34例,采用NP方案化疗:长春瑞滨(NVB)25mg/m2,第1,8天;顺铂30mg/m2,第1~3天,静滴。21d为1周期。治疗组34例,在化疗的同时加康莱特注射液100mL,静滴,每日1次,21d为1周期。均用2周期评价疗效。结果近期疗效:治疗组有效率47.1%,对照组为44.1%;Karnofsky评分好转率分别为64.7%和41.2%(P<0.05);治疗组T淋巴细胞亚群治疗前后无明显变化,对照组各指标均较治疗前下降。治疗组恶心、呕吐发生率为38.2%,对照组为44.1%。治疗组白细胞下降发生率为64.7%,对照组为82.4%(P<0.05)。结论康莱特注射液配合化疗治疗非小细胞肺癌可改善患者生活质量,减轻化疗药物的毒副反应,保护免疫功能,增强化疗耐受性。

关 键 词:康莱特注射液  非小细胞肺癌  长春瑞滨  顺铂

A Clinical Study on Kanglaite Injection Combined with Chemical Therapy in the Treatment of Patients with Advanced Non - Small Cell Lung Cancer
HOU Encun.A Clinical Study on Kanglaite Injection Combined with Chemical Therapy in the Treatment of Patients with Advanced Non - Small Cell Lung Cancer[J].Traditional Chinese Drug Research & Clinical Pharmacology,2008,19(6).
Authors:HOU Encun
Abstract:Objective To observe the curative effects and adverse reactions of Kanglaite Injection (KI) combined with chemotherapy of vinorelbine and cisplatin(NP) on advanced non-small cell lung cancer. Method Sixty-eight patients diagnosed pathologically as non-small cell lung cancer were randomly divided into two groups. The control group(n=34)was treated with chemotherapy of vinorelbine (25mg/m2,iv on the 1st and 8th day)combined with cisplatin (30mg/m2,iv from the 1st to 3rd day),and the treatment group was given 100 mL of KI besides the same treatment as the control group for 21 days. One cycle of treatment was 21 days. After 2 cycles,the curative effects were evaluated. Result The effective rate was 47.1 %in the treatment group and 44.1% in the control group(P>0.05). The improvement rate evaluated by karnofsky score was 64.7% in the treatment group and 41.2% in the control group,the difference being significant (P<0.05). T lymphocyte subtypes remained unchanged in the treatment group,while decreased in the control group as compared with those before treatment. The incidence of nausea and vomit was 38.2% in the treatment group and 44.1 %in the control group,and that of leukocyte decrease was 64.7% in the treatment group and 82.4% in the control group,the difference being significant (P<0.05). Conclusion The combination of KI with chemotherapy for treating non-small cell lung cancer can reduce the toxic and side effects of chemotherapy,protect immunity system,and improve the quality of life.
Keywords:Kanglaite Injection  Non-small cell lung cancer  Vinorelbine  Cisplatin
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号